ClinicalTrials.gg
TerminatedNCT04332705Crypto-KUpdated Nov 6, 2026

Cryptosporidium Infection and Human Colorectal Cancer

An observational study in Colonic Neoplasms and Cryptosporidiosis, sponsored by Lille Catholic University. Terminated at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Lille Catholic University · Observational

How we know

Why this study was terminated
No other patients could be included within the time frame.
Updated Nov 6, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
324,117
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 213 studies in Colonic Neoplasms with a site in France — 49 open to participants now, 66 under way, 13 of them phase 3. Colonic Neoplasms · France.

Enrollment
Largest of 55
324,117 · median 220
Started
2020
with 10 others
Observational
55 of 213
14 open now
Registered
142nd of 213
by date

Among the 213 studies in Colonic Neoplasms with a site in France, this one has the largest enrollment of the 55 observational ones that give a count, is one of 11 that started in 2020, is one of 55 observational ones, and was the 142nd registered.

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

49 of the 213 studies in Colonic Neoplasms with a site in France are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 213 studies in Colonic Neoplasms with a site in France, or all of them as a file.
02

Study summary

It has been reported that Cryptosporidium parvum, a species of a protozoan frequently isolated from humans and animals, is able to induce digestive adenocarcinoma in a rodent model. Consistently, some epidemiological studies have reported an association with cryptosporidiosis in patients with colorectal adenocarcinoma. However, the correlation between cryptosporidiosis and human digestive cancer remains unclear at this time, and it is not known whether this intracellular parasite, considered an opportunistic agent, is able to induce gastrointestinal malignancies in humans. In order to add new arguments for a probable association between cryptosporidiosis and digestive human cancer, the main aim of this study is to determine prevalence and to identify species of Cryptosporidium among a French digestive cancer population.

03

Conditions studied

  • Colonic Neoplasms
  • Cryptosporidiosis

Keywords

  • Colon cancer
  • Cryptosporidiosis
  • Prevalence
  • Infection and cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

The cases will be the patients with colon cancer of recent diagnosis recruited in consultation either in the surgical or gastroenterology departments. The controls will be the patients without colon cancer but with other gastrointestinal pathology needing a biopsy or a surgical procedure and recruited either in the surgical or gastroenterology departments

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Cases:

  • Age ≥ 18 years old
  • Patients with colonic adenocarcinoma/intraepithelial neoplasia diagnosed prior to chemotherapy or radiotherapy who will undergo scheduled surgery. Patients with rectal cancer with indication for treatment will still be included, but only used for diagnosis will be used
  • Patient capable of receiving informed information
  • Written
  • Affiliation to a social security scheme

Controls:

  • Age ≥ 18 years old
  • Patients with endoscopic indication for benign pathology
  • Patients with indication for colectomy for benign pathology
  • Patients with digestive cancer (stomach, oesophagus, biliary, pancreatic, etc.) of any type other than colorectal cancer before chemotherapy or radiotherapy
  • Patient capable of receiving informed information
  • Written informed consent
  • Affiliation to a social security scheme

Exclusion criteria

Exclusion Criteria:

  • Patients undergoing pre-operative chemotherapy.
  • Patients who have already had chemotherapy for less than one year or other treatment
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
324,117 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patients with colon cancer

    Patients with colon cancer of recent diagnosis will be recruited in consultation either in the surgical or gastroenterology departments

    Diagnostic Test: Detection of Cryptosporidium infection

  • Patients without colon cancer

    Patients without colon cancer but with other gastrointestinal pathology needing a biopsy or a surgical procedure will be recruited either in the surgical or gastroenterology departments

    Diagnostic Test: Detection of Cryptosporidium infection

Interventions

  • Diagnostic testDetection of Cryptosporidium infection

    A biopsy or a surgical sample will be collected from every participant

06

What researchers measure

Primary outcomes

  1. Prevalence of Cryptosporidium

    A biopsy or a surgical sample will be collected from every participant which will be then screened for Cryptosporidium using a Polymerase chain reaction (PCR) in order to obtain a prevalence of positive individuals

    Time frame: 3 years

Secondary outcomes

  1. Rate of occurrence of parasite development in the tumoral zone (yes/no) compared to the peri-tumoral zone.

    A biopsy or a surgical sample containing the tumoral and peri-tumoral areas will be collected only from the cases which will be then screened for Cryptosporidium using PCR

    Time frame: 3 years

  2. Significance of the association between the histological grade of the lesion and the Cryptosporidium species

    Significance of the association between the histological grade defined by the Vienna classification of tumors and the species of Cryptosporidium and the Cryptosporidium species.The main species of Cryptosporidium infecting humans are C. parvum and C. hominis, however, other species can also infect humans.

    Time frame: 3 years

  3. Significance of the association between the histological grade of the lesion and the parasitic charge in tissues

    Significance of the association between the histological grade defined by the Vienna classification of tumors and the species of Cryptosporidium and the parasitic charge in the tissues that will be determined by quantitative polymerase chain reaction (qPCR)

    Time frame: 3 years

  4. The rate of change in the expression or localization of certain markers known or suspected to be involved in the process of carcinogenesis.

    Some markers known to be associated to cancer development will be explored such as: Beta-catenin, P53, APC (adenomatous polyposis coli), etc.

    Time frame: 3years

  5. The association between the rate of lymphocytes (CD3, CD4, CD8, CD19 and CD4/CD8 ratio) and the presence of parasites in biopsies or surgical specimens

    Because Cryptosporidium is an opportunistic agent that causes significant morbidity and mortality in immunocompromised patients, it is possible that individuals with malignancies, have a higher risk of developing infection with this parasite, especially when their immunosuppression is more severe. To rule out this possibility this association will be determined.

    Time frame: 3 years

  6. Rate of development of a neoplastic lesion in the human explants

    A three-dimensional culture model will be developed using colon samples from healthy tissues of several control patients. An experimental Cryptosporidium infection will be tested in order to determine the development of neoplastic lesions in these human explants.

    Time frame: 3 years

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jun 2020 to primary completion in Jun 2025, 59 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Jun 2024 → Jun 2025 and completion Dec 2024 → Jun 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2020
First posted
Apr 3, 2020
StartActual
Jun 30, 2020
Primary completionActual
Jun 6, 2025was Jun 2024
CompletionActual
Jun 8, 2025was Dec 2024
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated No other patients could be included within the time frame.
changed Nov 6, 2026
Primary completion
Jun 30, 2024→Jun 6, 2025 (actual)
Nov 6, 2026
Study completion
Dec 30, 2024→Jun 8, 2025 (actual)
Nov 6, 2026
Enrollment
324 (estimated)→324117 (actual)
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Recruiting→Terminated
    Why stopped No other patients could be included within the time frame.
    Primary completion Jun 30, 2024→Jun 6, 2025 (now actual)
    Study completion Dec 30, 2024→Jun 8, 2025 (now actual)
    Enrollment 324 (estimated)→324117 (actual)
    + 4 other changes: index terms, verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04332705
Collaborators
Institut Pasteur de Lille
Responsible party
Sponsor
First posted
Apr 3, 2020
Start date
Jun 30, 2020
Primary completion
Jun 6, 2025
Completion
Jun 8, 2025
Last update
Nov 6, 2026

Study contacts

Bertrand Nunes, MD
study director · GHICL
Gabriela Certad, MD, PhD
principal investigator · GHICL

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion